转向低全球变暖潜力的材料兼容性考虑 压力计量剂量吸入器的推进剂
Dan Dohmeier1, Atish Sen2, Alessandro Cavecchi3
1Kindeva Drug Delivery L.P., Woodbury, Minnesota, USA.
AAPS PharmSciTech
|February 18, 2025
概括
制药行业正在将压力计量剂量吸入器 (pMDI) 转换为低全球变暖潜力 (GWP) 推进剂. 这种转变利用了过去的经验,以确保喘和COPD等肺部疾病治疗的持续有效性.
科学领域:
- 制药气溶是制药气溶中的一种.
- 环境科学 环境科学
- 材料科学 材料科学 材料科学
背景情况:
- 压力计量剂量吸入器 (pMDI) 对于治疗喘和COPD等肺部疾病至关重要.
- 目前在pMDIs中的化碳 (HFC) 推进剂具有高的全球变暖潜力 (GWP).
- 环境法规要求向低GWP推进剂过渡.
研究的目的:
- 讨论pMDI组件与低GWP推进剂的材料兼容性.
- 为了利用从以前的CFC到HFC过渡中学到的知识.
- 描述用于pMDIs的低GWP推进剂的实用性和发展状态.
主要方法:
- 审查有关低GWP推进剂的现有文献.
- 对pmdi组件的材料兼容性数据的分析.
- 利用从化碳 (CFC) 到化碳 (HFC) 过渡的历史数据.
主要成果:
- 工业已经准备好过渡到低GWP推进剂.
- 从CFC切换到HFC切换的学习正在应用中.
- 针对pmdi的低GWP推进剂的开发正在取得进展.
结论:
- 在pMDIs中向低GWP推进剂的过渡是可行的.
- 材料的兼容性是成功实施的关键考虑因素.
- 持续的研究和开发将确保有效和对环境负责任的肺病疗法.
相关概念视频
Inhaled Medications
219
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
219
Inhalational Anesthetics: Overview
166
Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
166
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Methylxanthines
187
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
187
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
145
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
145
Antiasthma Drugs: Leukotriene Modifiers
238
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
238


